Marian Chu

2 days ago | bioworld.com | Marian Chu

Home » Abion strikes $1.3B antibody drug deal with unidentified partner BioWorld briefs for June 25, 2025. BioWorld MedTech briefs for June 24, 2025. Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...

4 days ago | bioworld.com | Marian Chu

Home » Moderna expands mRNA tech to latent viruses, cancer, rare disease BioWorld briefs for June 23, 2025. BioWorld MedTech briefs for June 23, 2025. BioWorld Asia briefs for June 24, 2025 Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd.... In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc.

4 days ago | bioworld.com | Marian Chu

Illumina buying Somalogic for up to $425M to boost multiomics assetsIn a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc. from Standard Biotools Inc. for...

4 days ago | bioworld.com | Marian Chu

Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.

4 days ago | bioworld.com | Marian Chu

Shanghai Yao Yuan Biotechnology Ltd., also known as Drug Farm, is advancing a portfolio of immune-modulating therapies for various indications including hepatitis B virus (HBV), hepatocellular cancer (HCC) and a relatively new rare genetic disease called ROSAH, an acronym for retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache.